Emmanuelle Bompas

13.0k total citations · 1 hit paper
197 papers, 5.8k citations indexed

About

Emmanuelle Bompas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Emmanuelle Bompas has authored 197 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pulmonary and Respiratory Medicine, 86 papers in Oncology and 35 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Emmanuelle Bompas's work include Sarcoma Diagnosis and Treatment (129 papers), Vascular Tumors and Angiosarcomas (35 papers) and Cardiac tumors and thrombi (35 papers). Emmanuelle Bompas is often cited by papers focused on Sarcoma Diagnosis and Treatment (129 papers), Vascular Tumors and Angiosarcomas (35 papers) and Cardiac tumors and thrombi (35 papers). Emmanuelle Bompas collaborates with scholars based in France, United States and Italy. Emmanuelle Bompas's co-authors include Jean‐Yves Blay, Nicolas Penel, Antoîne Italiano, Nicolás Isambert, Sophie Piperno‐Neumann, Christine Chevreau, Florence Duffaud, François Bertucci, Didier Cupissol and Isabelle Ray‐Coquard and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emmanuelle Bompas

184 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

2018 229 citations Florence Duffaud, Olivier Mir et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emmanuelle Bompas France	38	4.1k	2.6k	1.2k	1.2k	912	197	5.8k
David R. D’Adamo United States	30	3.2k 0.8×	2.6k 1.0×	980 0.8×	821 0.7×	558 0.6×	65	4.9k
Kristen N. Ganjoo United States	35	3.3k 0.8×	2.0k 0.7×	539 0.5×	613 0.5×	1.1k 1.2×	172	5.3k
Scott M. Schuetze United States	43	6.4k 1.5×	3.3k 1.3×	2.0k 1.7×	1.5k 1.3×	1.3k 1.4×	167	8.7k
Rossella Bertulli Italy	25	3.9k 1.0×	1.5k 0.6×	1.5k 1.2×	633 0.5×	1.2k 1.3×	82	5.1k
Javier Martín‐Broto Spain	35	3.2k 0.8×	1.6k 0.6×	691 0.6×	559 0.5×	1.2k 1.3×	226	4.5k
Dominique Ranchère‐Vince France	32	3.0k 0.7×	1.4k 0.5×	1.2k 1.0×	662 0.6×	526 0.6×	89	3.9k
Frits van Coevorden Netherlands	42	4.2k 1.0×	3.1k 1.2×	1.1k 0.9×	1.6k 1.3×	1.9k 2.0×	127	6.2k
Philippe A. Cassier France	43	3.2k 0.8×	4.0k 1.5×	735 0.6×	368 0.3×	1.1k 1.2×	295	7.4k
Louis Guillou Switzerland	50	5.8k 1.4×	2.8k 1.1×	2.4k 2.1×	1.8k 1.6×	1.1k 1.2×	116	8.1k
Mary Louise Keohan United States	34	2.8k 0.7×	2.2k 0.8×	718 0.6×	627 0.5×	354 0.4×	105	4.4k

Countries citing papers authored by Emmanuelle Bompas

Since Specialization

Citations

This map shows the geographic impact of Emmanuelle Bompas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuelle Bompas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuelle Bompas more than expected).

Fields of papers citing papers by Emmanuelle Bompas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuelle Bompas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuelle Bompas. The network helps show where Emmanuelle Bompas may publish in the future.

Co-authorship network of co-authors of Emmanuelle Bompas

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuelle Bompas. A scholar is included among the top collaborators of Emmanuelle Bompas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuelle Bompas. Emmanuelle Bompas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vanacker, Hélène, Nicolas Penel, Sarah Watson, et al.. (2025). Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study. Cancer. 131(18). e70052–e70052. 1 indexed citations

Penel, Nicolas, Antoîne Italiano, Jennifer Wallet, et al.. (2025). Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. Annals of Oncology. 36(8). 944–953.

Peyraud, Florent, Jean‐Philippe Guégan, Jean‐Yves Blay, et al.. (2025). 2687MO CONgRAtS: A randomized phase II study of nivolumab±relatlimab in patients with TLS-positive soft-tissue sarcomas. Annals of Oncology. 36. S1338–S1339.

Wallet, Jennifer, L. Chaigneau, Nelly Firmin, et al.. (2024). 1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts). Annals of Oncology. 35. S1030–S1030. 1 indexed citations

Penel, Nicolas, Daniel Orbach, Véronique Minard‐Colin, et al.. (2023). Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age. SHILAP Revista de lepidopterología. 1. 100012–100012.

Brahmi, Mehdi, Olivier Trédan, Nicolas Penel, et al.. (2023). Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.. Journal of Clinical Oncology. 41(16_suppl). 11545–11545. 1 indexed citations

Duffaud, Florence, Jean‐Yves Blay, Axel Le Cesne, et al.. (2023). Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. British Journal of Cancer. 129(12). 1940–1948. 17 indexed citations

Penel, Nicolas, Sylvie Bonvalot, Alexandra Meurgey, et al.. (2022). Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis. Clinical Cancer Research. 28(18). 4105–4111. 13 indexed citations

Saint‐Jean, M., Judith Raimbourg, Mathieu Artifoni, et al.. (2021). Ulcérations nécrotiques des membres inférieurs sous sunitinib. 1(8). A321–A322.

10.

Bompas, Emmanuelle, Maud Toulmonde, Perrine Marec‐Bérard, et al.. (2021). Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bulletin du Cancer. 108(2). 163–176. 5 indexed citations

11.

Boudou‐Rouquette, Pascaline, E. Martin, Emmanuelle Kempf, et al.. (2021). Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. International Journal of Cancer. 150(5). 825–836. 1 indexed citations

12.

Duffaud, Florence, Jean‐Yves Blay, Olivier Mir, et al.. (2020). LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Annals of Oncology. 31. S1199–S1199. 13 indexed citations

13.

Cesne, Axel Le, Perrine Marec‐Bérard, Jean‐Yves Blay, et al.. (2019). Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer. 119. 151–157. 114 indexed citations

14.

Toulmonde, Maud, Jean‐Yves Blay, Olivier Bouché, et al.. (2019). Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clinical Cancer Research. 25(15). 4611–4615. 14 indexed citations

15.

Piperno‐Neumann, Sophie, Isabelle Ray‐Coquard, Bob‐Valéry Occéan, et al.. (2019). Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study. International Journal of Cancer. 146(2). 413–423. 27 indexed citations

16.

Stoeckle, Eberhard, C. Le Péchoux, Pierre Méeus, et al.. (2018). Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 102(2). 399–406. 31 indexed citations

17.

Brodowicz, Thomas, Olivier Mir, Jennifer Wallet, et al.. (2018). Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer. 99. 28–36. 15 indexed citations

18.

Italiano, Antoîne, Valérie Laurence, Nicolas Penel, et al.. (2017). A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. Scientific Reports. 7(1). 17917–17917. 8 indexed citations

19.

Ray‐Coquard, Isabelle, Antoîne Italiano, Emmanuelle Bompas, et al.. (2012). Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). The Oncologist. 17(2). 260–266. 148 indexed citations

20.

Duffaud, Florence, Caroline Even, Isabelle Ray‐Coquard, et al.. (2012). Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. SHILAP Revista de lepidopterología. 2(1). 11–11. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact